Wesley Day, PhD
Wesley Day, PhD is a clinical research and drug development expert with more than 20 years’ experience in the pharmaceutical industry. He currently serves as the Vice President, Clinical Development of VIVUS, Inc. He is responsible for all clinical programs at VIVUS as well as leading regulatory strategy and oversight of all clinical submissions. He oversees preclinical and clinical research, as well as clinical development including operations, data management, biostatistics and reporting. During his tenure at VIVUS, he has led the company’s efforts resulting in 3 successful NDA approvals: Evamist (2007), Qsymia (2012) and Stendra (2012), and the EU MAA approval for Spedra (2013). Dr. Day has extensive experience with the leadership of Health Authority interactions, negotiations and strategy (FDA, EMA and EU member states). He was Sponsor presenter and moderator for both Qsymia FDA Advisory panels, and also for the European CHMP Qsiva Oral Hearings. Qsymia was the first approved and marketed weight loss drug in the US in over 12 years. Prior to joining VIVUS, Dr. Day was at Pfizer for 13 years where he held a variety of positions of increasing responsibility in Discovery, Clinical Development and Regulatory Affairs.